of efficacy or poor tolerability is appropriate. Concerns were expressed regarding a highly fatal lung disease observed in some children with systemic JIA, most of whom were treated with bDMARDs. Observed risk factors include younger age with MAS, a history of reactions to tocilizumab, and trisomy 21 NSAIDs NSAIDs are conditionally recommended as initial monotherapy for systemic JIA without MAS. Studies suggest that a small proportion of patients with systemic JIA will respond to NSAIDs alone